We invite patients with MPNs on treatment, to complete this anonymous survey on a proposed study looking at the effect of changes in mutation levels in MPN patients on treatment.
Study Outline
The study will be led by MPN specialists, Dr Jennifer O’Sullivan and Dr Alesia Khan, with the support of the UK MPN clinical community. It will be run by the Cancer Research UK Clinical Trials Unit, University of Birmingham. The proposed study will explore how mutation levels (JAK2V617F/CALR/MPL) change with treatments in MPNs and how these changes relate to clinical outcomes. The mutation level (allele burden) in MPN represents the proportion of blood cells carrying the mutation. A decrease in allele burden (molecular response) may suggest that the MPN is better controlled and potentially lead to improved outcomes, such as lower risk of disease progression or reduced use of treatments with side effects.
The goal of the study is to understand whether monitoring molecular responses can be used to help doctors make better treatment decisions for patients.
Click on the button below to complete the survey, it will take approximately 2 minutes to complete.
The study team will also be setting-up a focus group for the study, if you are interested in participating please email info@mpnvoice.org.uk.
